Navigation Links
Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
Date:2/27/2013

nings increased $40.3 million or 17.8% to $266.9 million for the three months ended December 31, 2012 as compared to adjusted earnings of $226.6 million for the prior year comparable period.

EBITDA, which is defined as net income (excluding the non-controlling interest and income from equity method investees) plus income taxes, interest expense, depreciation and amortization, was $398.5 million for the quarter ended December 31, 2012, and $334.0 million for the comparable prior year period.  After adjusting for certain items as further detailed below, adjusted EBITDA was $462.4 million for the current three-month period and $406.6 million for the comparable prior year period. 

Year Ended December 31, 2012For the year ended December 31, 2012, Mylan reported total revenues of $6.80 billion compared to $6.13 billion in the comparable prior year period. Third party net revenues for the year ended December 31, 2012 were $6.75 billion compared to $6.11 billion for the comparable prior year period, representing an increase of $644.0 million, or 10.5%. Revenues were unfavorably impacted by the effect of foreign currency translation, generally reflecting a stronger U.S. Dollar as compared to the currencies in other major markets in which Mylan operates. Translating third party net revenues at prior year exchange rates would have resulted in year over year increase in third party net revenues, excluding foreign currency, of $840 million, or approximately 14%.

Generics third party net revenues were $5.95 billion for the year ended December 31, 2012, compared to $5.56 billion in the comparable prior year period, representing an increase of $391.2 million, or 7.0%, or an increase of approximately 11% when excluding the unfavorable effect of foreign currency translation.

Third party net revenues from North America were $3.26 billion for the year ended December 31, 2012, compared to $2.86 billion for the comparable prior year period, re
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
2. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
3. Mylan Schedules Fourth Quarter and Year End 2012 Financial Results Conference Call and Live Webcast
4. Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors
5. Mylan Announces Pricing of Senior Notes
6. Moodys and Standard & Poors Upgrade Mylan to Investment Grade Credit Ratings
7. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
8. Mylan Selected as a Leading ARV Supplier to Indias National AIDS Control Organization
9. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
10. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
11. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Novastem, a leader in regenerative medicine, ... its study for ischemic stroke at Clinica Santa ... strokes account for 87 percent of all stroke ... the study, entitled "Internal Research Protocol in Combination ... Cells and Intrathecal Administration of Neural Stem Cells ...
(Date:12/24/2014)... Pa. , Dec. 24, 2014  Commonwealth Cornerstone Group ... Markets Tax Credits transaction on Tuesday to help fund the ... Network (PHN) in Sharon . ... in Pennsylvania . It is the largest ... with more than 150 people on staff. Currently, ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... OMER ) today announced that its exclusive license to ... been amended to include addiction and compulsive disorders in the ... Company,s discovery of a previously unknown link between PDE7 and ... it also is the first to link PDE7 to any ...
... BRUNSWICK, N.J. and LEIDEN, Netherlands, Feb. 22, 2011 Johnson ... (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) ... offer for Crucell N.V. (Crucell) and has declared the offer ... center for vaccines within the Johnson & Johnson pharmaceuticals group. ...
Cached Medicine Technology:Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 3Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 4Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 2Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 3Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 4Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 5Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 6Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 7Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 8
(Date:12/24/2014)... 2014 Over 700 toys, that’s what ... communities. That is 700 smiling little faces this holiday ... over $6000 in monetary donations was given to the ... the expenses they incur through the year. Some of ... A Child's Haven , Shrine's Children's Hospitals, Toys for ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... to mount in a mass tort litigation currently underway ... LLP reports. As of December 24, 2014, court ... the proceeding on behalf of individuals who developed gynecomastia ... its use. Data from the Court indicates that this ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Dr. ... announced the expansion of his practice and med-spa with ... the practice’s growing list of cosmetic treatments and services. ... solution into the skin,” says Dr. Ho. “As a ... changes such as wrinkles, sun spots, discolorations or blemishes.” ...
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, has ... launched a site-wide wedding gown promotion. , For ... a more unexpected way, the collection should be a great ... global market, and they are available with custom service. , ... discounted prices, up to 75% off; most of them come ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... LUGANO, SWITZERLAND, June 4, 2008 Finbarr Cotter, M.D., ... Science at Barts and The London School of Medicine, ... in CLL by GCS-100: a Phase 2 Study" at ... The promising interim results from this ongoing clinical trial ...
... Will be Held in Berlin ... from 22 to 24 September, BERLIN, June ... disablement? Experts from,throughout the world will address this question at the 4th ... Berlin,Congress Centre from 22 to 24 September 2008. The IFDM will be ...
... Offerings, MOUNTAINSIDE, N.J., June 4 L&M ... the opening of a new full-service Midwest office ... as Vice President, Client Services., These enhancements ... and better meet the needs of their growing ...
... M. Redstone to Accept Award At June 9 ... ... Global Business,Coalition on HIV/AIDS, Tuberculosis and Malaria (GBC) announced today that,it will ... Excellence at its June 9th annual,celebration. The GBC, an organization of more ...
... Scientists at Karolinska Institutet in Sweden and Miami University have ... in a way hitherto unknown. The discovery can eventually be ... aim of the project was to find out how the ... known for a long time that glucose is regulated with ...
... Monitoring extreme weather, such as periods of high ... intensity of infectious diseases like cryptosporidiosis, an intestinal disease ... researchers have created a model that takes into account ... people who will fall ill during an outbreak. With ...
Cached Medicine News:Health News:Clinical study shows biological and clinical activity in relapsed leukemia patients 2Health News:Clinical study shows biological and clinical activity in relapsed leukemia patients 3Health News:Retaining Employees' Capacity For Work Following Sickness 2Health News:L&M Healthcare Communications LLC Expands With Hiring of New Executive Staff & Opening of Midwest Office 2Health News:Viacom to Receive Leadership Award for Business Excellence from The Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria for Its 25 Years of Work on HIV/AIDS Education and Advocacy 2Health News:Viacom to Receive Leadership Award for Business Excellence from The Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria for Its 25 Years of Work on HIV/AIDS Education and Advocacy 3Health News:Discovery of new signal pathway important to diabetes research 2Health News:Weather, stomach bugs and climate change: Refining the model 2
... The CKX microscopes utilize ... improved visibility and operability in ... a cost-effective inverted microscope suited ... range of fields--from tissue culture ...
The simplest, neatest, most efficient anti-theft system for frames and sunwear. Available in 3 colors Black, Matte aluminum, and Bronze. Fits with any style or color of furniture. Safe, simple, easy...
69" 5 shelves electric rotating display with gunmetal grey frame. Lead time 6-8 weeks....
1 Frame clear base post with transparent Eyevee 2.0 Clip....
Medicine Products: